Performance of standard systematic biopsy versus MRI/TRUS fusion biopsy using the Navigo ® system in contemporary cohort

CONCLUSIONS: Detection of csPca by mpMRI/TRUS fusion biopsy using the 3D Navigo™ system is feasible. The targeted approach outperforms the systematic one, however the later technique also detects high risk disease and should be included in the biopsy procedure. The overall detection rate (34.9%) of clinically significant prostate cancer by both targeted and systematic sampling is relatively low.PMID:38431487 | DOI:10.1016/j.urolonc.2024.01.026
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Source Type: research